Transcription of New response evaluation criteria in solid tumours: Revised ...
{{id}} {{{paragraph}}}
New response evaluation criteria in solid tumours: Revised RECIST guideline (version ) Eisenhauera,*, P. Therasseb, J. Bogaertsc, Schwartzd, D. Sargente, R. Fordf,J. Danceyg, S. Arbuckh, S. Gwytheri, M. Mooneyg, L. Rubinsteing, L. Shankarg, L. Doddg,R. Kaplanj, D. Lacombec, J. VerweijkaNational Cancer Institute of Canada Clinical Trials Group, 10 Stuart Street, Queen s University, Kingston, ON, CanadabGlaxoSmithKline Biologicals, Rixensart, BelgiumcEuropean Organisation for Research and Treatment of Cancer, Data Centre, Brussels, BelgiumdMemorial Sloan Kettering Cancer Center, New York, NY, USAeMayo Clinic, Rochester, MN, USAfRadPharm, Princeton, NJ, USAgDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USAhSchering-Plough, Kenilworth, NJ, USAiEast Surrey Ho
Response criteria Solid tumours Guidelines ABSTRACT Background: Assessment of the change in tumour burden is an important feature of the clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and disease progression are useful endpoints in clinical trials. Since RECISTwas published
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}